From 1997 to 2020, the prevalence of obesity in the adult population increased steadily in France. However, obesity rates have grown unequally among different age groups. From 1997 to 2020, the share of obese people was higher among older people. In 2020, roughly 20 percent of people aged 55 to 64 suffered from obesity in France.

These figures revealed one exception among the eldest age group. Indeed, among French people aged 65 or older, obesity prevalence decreased from 2012 to 2020. As a result, during this period, obesity rates among 55-64 year olds surpassed that among 65 and over 65 year olds.

This statistic displays the prevalence of childhood obesity* in France from 1975 to 2016, by gender. Since the beginning of this time series, there has been a greater prevalence of childhood obesity among male children in France than among females.

From 1997 to 2020, the prevalence of obesity in the adult population increased steadily in France. In 1997, less than nine percent of adults were obese in France. By 2020, the prevalence of obesity had increased to 17 percent. At this rate, obesity could soon touch one in five adults in France.

From 1997 to 2020, the prevalence of obesity in the adult population increased steadily in France. However, obesity rates have unequally grown among men and women. From 1997 to 2003, the share of obese men was higher than that of women. In 1997, roughly 8.8 percent of men were obese in France, compared to 8.3 percent of women. By 2006, the prevalence of obesity among French women was higher than for men. In 2020, roughly 16.7 percent of men and 17.4 percent of women suffered from obesity in France.

Background: Growth charts are an essential clinical tool for evaluating a child's health and development. The current French reference curves, published in 1979, have recently been challenged by the 2006 World Health Organization (WHO) growth charts. Objective: To evaluate and compare the growth of French children who were born between 1981 and 2007, with the WHO growth charts and the French reference curves currently used. Design: Anthropometric measurements from French children, who participated in 12 studies, were analyzed: 82,151 measurements were available for 27,257 children in different age groups, from birth to 18 years. We calculated and graphically compared mean z-scores based on the WHO and French curves, for height, weight and Body Mass Index (BMI) according to age and sex. The prevalence of overweight using the WHO, the French and International Obesity Task Force definitions were compared. Results: Our population of children was on average 0.5 standard deviations taller than the French reference population, from the first month of life until puberty age. Mean z-scores for height, weight and BMI were closer to zero based on the WHO growth charts than on the French references from infancy until late adolescence, except during the first six months. These differences not related to breastfeeding rates. As expected, the prevalence of overweight depended on the reference used, and differences varied according to age. Conclusion: The WHO growth charts may be appropriate for monitoring growth of French children, as the growth patterns in our large population of French children were closer to the WHO growth charts than to the French reference curves, from 6 months onwards. However, there were some limitations in the use of these WHO growth charts, and further investigation is needed.

In 2020, the prevalence of obesity in the adult population stood at 17 percent in France, yet varied greatly from one region to another. During that year, obesity prevalence ranged from 14 percent, in Ile-de-France, to over 22 percent, in Hauts-de-France. Interestingly, the two regions with the second and third highest obesity rates were also northern, Normandie and Grand-Est.

SD: Standard Deviation; IOTF: International Obesity Task ForceC-25 and C-30 correspond to centiles that match BMI 25 and 30 kg/m2 at 18 years†WHO > 1 SD correspond to WHO > 85th‡WHO > 2 SD correspond to WHO > 97.7th*Overweight includes ‘obesity’**At risk of overweight includes ‘overweight’ and ‘obesity’Percentage of children classified as overweight (including obesity), obese and at risk of overweight.

The French bariatric surgery market is experiencing robust growth, fueled by a rising prevalence of obesity and associated health complications. The market, valued at approximately €200 million in 2025 (estimated based on provided CAGR and regional market comparisons), is projected to maintain a Compound Annual Growth Rate (CAGR) of 13.20% from 2025 to 2033. This growth is driven by increased awareness of bariatric surgery as an effective weight-loss solution, improved surgical techniques leading to reduced complications and shorter recovery times, and expanding insurance coverage for these procedures. Furthermore, the increasing adoption of minimally invasive techniques and advanced technologies like robotic surgery contribute significantly to market expansion. The market segmentation reveals a strong demand for assisting devices, particularly implantable ones, reflecting the growing sophistication of surgical procedures and the need for improved patient outcomes. Leading players like Stryker, Johnson & Johnson, and Medtronic are actively driving innovation and market penetration through product development and strategic collaborations. However, despite the positive growth trajectory, the market faces certain constraints. These include the high cost of surgery, potentially limiting access for a segment of the population, and the possibility of long-term complications associated with bariatric procedures. Furthermore, regulatory hurdles and the need for skilled surgical professionals can pose challenges to market growth. Nevertheless, the ongoing development of less invasive procedures, coupled with government initiatives aimed at combating obesity, is expected to mitigate these challenges and sustain market expansion throughout the forecast period. The continued focus on improving patient care and outcomes, coupled with technological advancements, will be crucial in shaping the future of the French bariatric surgery market. Recent developments include: July 2022: University Hospital, Bordeaux sponsored a clinical study on the effectiveness of the use of VERT on improving body image at 12 months in patients who underwent bariatric surgery in the weight stabilization phase. The study is expected to be completed by 2024., February 2022: Assistance Publique - Hopitaux de Paris sponsored a clinical study aiming to assess the impact of surgical bariatric treatment on the improvement of pancreatic lesions detected by magnetic resonance imaging (MRI) in France.. Key drivers for this market are: Increase in Obese Patients, Government Initiatives to Curb Obesity. Potential restraints include: High Cost of Surgery. Notable trends are: Stapling Devices Segment is Expected to Grow Significantly over the Forecast Period.

France Bariatric Surgery Market size was valued at USD 1.32 Billion in 2024 and is projected to reach USD 2.62 Billion by 2031, growing at a CAGR of 9.1% from 2024 to 2031.

France Bariatric Surgery Market Drivers

Rising Obesity Rates: The increasing prevalence of obesity in France is a major driver of the bariatric surgery market. According to the French National Institute for Health and Medical Research (INSERM), over 17% of the adult population in France is classified as obese, with numbers continuing to rise. A growing number of people are considering bariatric surgery as a therapeutic option to enhance their quality of life and avoid additional health risks because obesity causes a number of health issues, including diabetes, cardiovascular illnesses, and insomnia. Government Initiatives and Healthcare Funding: The French government has been actively investing in healthcare to combat the growing obesity epidemic. A larger population now has easier access to bariatric surgery because to France's recent expansion of its national health insurance coverage for the treatment. In 2022, the French Ministry of Health announced plans to increase funding for bariatric surgeries as part of its strategy to reduce obesity-related health burdens, thus providing a boost to the market. Technological Advancements in Surgical Procedures: Advancements in surgical technologies, particularly minimally invasive techniques such as laparoscopic and robotic-assisted surgeries, are contributing to the growth of the bariatric surgery market in France. These methods give patients less wounds, fewer problems, and quicker recovery times. More sophisticated robotic technologies, such as the da Vinci Surgical System, have improved the accuracy and security of bariatric procedures, making them more desirable to patients and surgeons alike. Growing Awareness and Acceptance of Bariatric Surgery: Increased awareness about obesity and the benefits of bariatric surgery is also driving market growth. The demand for bariatric surgery is rising as more patients become aware of the benefits of these treatments, including significant weight loss and a reduction in comorbidities associated with obesity.

This statistic displays the prevalence of adolescent obesity* in France from 1975 to 2016, by gender. In 1975, the prevalence of obesity among French adolescents showed no gender differences. While the obesity rate has increased for both male and female adolescents over the intervening years, male adolescents in France were more likely to be obese than female adolescents as of 2016.

DGESCO, Direction Générale de l'Enseignement SCOlaire; ELANCE, Etude Longitudinale Alimentation Nutrition Croissance des Enfants; ENNS, Etude Nationale Nutrition Santé; ICAPS, Intervention Centered on Adolescents’ Physical activity and Sedentary behavior; INCA 2, Etude Individuelle Nationale des Consommations Alimentaires; InVS, Institut de Veille Sanitaire; IRSA, Institut inter Régional pour la Santé; PNNS, Programme National Nutrition Santé.†age at inclusion for prospective studiesCharacteristics of the studies used for analyses of children from 5 years to 18 years.

From 1997 to 2020, the prevalence of overweight and obesity in the adult population increased steadily in France. In 1997, over 38 percent of adults were overweight or obese in France. By 2020, the prevalence of obesity had increased to 47 percent. However, the share of overweight and obesity in France remained stable from 2012 to 2020.

Snapshot img

Anti-Obesity Drugs Market Size 2025-2029

The anti-obesity drugs market size is forecast to increase by USD 22.91 billion at a CAGR of 15.7% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising obesity population, particularly in North America, is a major driver for this market. Additionally, research and development efforts are focused on creating drugs that can effectively manage both obesity and type 2 diabetes mellitus. This dual-action approach is gaining popularity as many obese individuals are also at risk for developing type 2 diabetes. Furthermore, the availability of telemedicine services and anti-obesity devices is making weight management more accessible and convenient for individuals. These trends are expected to continue fueling the growth of the market In the coming years. The use of anti-obesity drugs can help regulate insulin production and manage weight by reducing appetite and increasing metabolism. These drugs can have a positive impact on overall health and well-being, making them an essential tool In the fight against obesity and related health conditions.

What will be the Size of the Anti-Obesity Drugs Market During the Forecast Period?

Request Free Sample

The market encompasses a range of medicines designed to assist individuals struggling with weight management, targeting conditions such as obesity and overweight. These conditions are often linked to chronic diseases, including insulin resistance, glucose intolerance, hypertension, sleep apnea, diabetes mellitus, arthritis, and various lifestyle-related illnesses. The prevalence of obesity and overweight continues to rise globally, driven by energy imbalance, with calories consumed exceeding calories expended. Factors contributing to this imbalance include appetite stimulation, metabolic disorders, and fat absorption. The market for anti-obesity drugs is expected to grow significantly due to the increasing burden of obesity and its associated health complications.
This trend is driven by the growing awareness of the health risks associated with obesity and the desire for effective weight loss solutions. The market caters to both adults and children and adolescents, addressing the rising prevalence of obesity across all age groups. The market's growth is further fueled by the increasing incidence of lifestyle-related factors, such as stress, smoking, and drinking, which contribute to weight gain.

How is this Anti-Obesity Drugs Industry segmented and which is the largest segment?

The anti-obesity drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Class III
  Class II anti-obesity drugs
  Class I anti-obesity drugs


Drug Class

  Peripherally acting drugs
  Centrally acting drugs


Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Drug stores
  E-commerce


Route Of Administration

  Oral route
  Subcutaneous route


Geography

  North America

    Canada
    Mexico
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    Japan


  Rest of World (ROW)

By Type Insights

The class III segment is estimated to witness significant growth during the forecast period. The Class III segment dominates The market due to its focus on addressing severe obesity cases. This segment accounts for a significant market share and is expected to continue its leadership during the forecast period. The rise in research and development initiatives by pharmaceutical companies for novel anti-obesity drugs contributes to market expansion. However, it's important to note that pharmacotherapy for obesity can only achieve a certain reduction in Body Mass Index (BMI). Consequently, the Class III anti-obesity drugs segment may witness a decline during the forecast period as patients may require additional measures for sustained weight loss.
Obesity is a chronic condition with a global prevalence that fuels the demand for weight-loss medicines. These medicines target various mechanisms such as appetite suppression, metabolism enhancement, and fat absorption inhibition. Prevalent conditions associated with obesity include cardiovascular diseases, cancers, type-2 diabetes, and sleep apnea. The market caters to various distribution channels, including retail pharmacies, online pharmacies, and hospital pharmacies. Anti-obesity drugs can be administered through oral and subcutaneous routes.

Get a glance at the market report of share of various segments Request Free Sample

The class III segment was valued at USD 6.85 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 71% to the growth o

France Food Sweetener Market size is expected to develop revenue and exponential market growth at a remarkable CAGR from 2026 to 2032.

Key Market Drivers:

Health Consciousness: Growing awareness of the health risks associated with excessive sugar consumption is driving consumers to seek healthier alternatives. This trend is reflected in the increasing demand for low-calorie and sugar-free sweeteners, as more individuals prioritize their health and well-being.

Rising Obesity Rates: The increasing prevalence of obesity in France has led to a greater adoption of low-calorie sweeteners. According to the French National Institute for Health and Medical Research, approximately 17% of adults were classified as obese in 2022, prompting a shift towards healthier dietary choices.

This statistic shows the percentage of French people suffering from obesity in 2013, by department. That year, 22.9 percent of the inhabitants of Meurthe-et-Moselle were obese.

As of 2020, roughly one out of two adults were overweight or obese in France. During that year, around 47 percent of French adults had a BMI of over 25, which the index classifies as overweight. Nonetheless, only 17 percent of adults fell under the obesity classification: a BMI of at least 30.

Snapshot img

Bariatric Surgical Devices Market Size 2024-2028

The bariatric surgical devices market size is estimated to grow by USD 588.8 million at a CAGR of 5.11% between 2023 and 2028. One major trend in the market is the surge in medical tourism for bariatric surgery, as patients travel internationally to access more affordable procedures. Another trend is the increasing use of robotic-assisted bariatric surgery, which offers advantages such as minimally invasive procedures and improved precision. However, the high cost of bariatric surgery remains a significant challenge for many patients, limiting access to this life-changing procedure. Despite this, the market is expected to continue growing due to the increasing prevalence of obesity and the proven effectiveness of bariatric surgery in improving overall health and quality of life.

What will be the Size of the Market During the Forecast Period?

For More Highlights About this Report, Request Free Sample

Market Dynamic and Customer Landscape

The market is driven by the increasing prevalence of obesity and its associated comorbidities, making bariatric surgery a popular medical approach for weight loss. This market encompasses various equipment and devices used in bariatric procedures, including gastrointestinal devices such as reversible implants (adjustable gastric bands) and intragastric balloons, as well as pharmaceutical devices. Bariatric surgery is used to treat obesity and its related conditions, including hypertension and gastrointestinal diseases. Advanced endoscopic techniques, robotic procedures, and minimally invasive approaches have gained popularity in recent years, reducing wound complications and improving patient outcomes. The market is expected to grow significantly due to the increasing number of hospitals, specialty centers, and ambulatory surgical centers offering these procedures. Artificial Intelligence is also being integrated into bariatric surgery to improve patient care and outcomes. Laparoscopic surgery and revision surgery are common procedures in this market, with the former being a minimally invasive approach that reduces hospital stays and recovery time. The use of these devices in weight loss procedures is essential for managing obesity, a public health problem that affects millions worldwide. In conclusion, the market is a growing industry that plays a crucial role in addressing the global obesity epidemic and its associated comorbidities. The market is expected to continue expanding due to advancements in technology, increasing demand for minimally invasive procedures, and the growing number of bariatric surgery centers. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The surge in medical tourism for bariatric surgery is notably driving market growth. Obesity, a major public health problem, necessitates effective solutions to manage comorbidities and promote weight loss. Bariatric surgery, a medical approach for obese individuals, employs various equipment and devices to facilitate the procedure. These include laparoscopic tools for minimally invasive approaches, and pharmaceutical devices for adjustable gastric banding. Bariatric surgery devices are used in procedures like sleeve gastrectomy, gastric bypass, and mini-gastric bypass. Complication rates for these procedures include wound complications, hospital stays, pain, internal hernias, gastroesophageal reflux disease, dumping syndrome, ulcers, malnutrition, inflammatory bowel disease, and incisions. Advanced endoscopic techniques, such as reversible implants, and robotic procedures, are also used to enhance safety and efficiency. Metabolic surgery devices play a crucial role in managing gastrointestinal diseases and improving patient outcomes. They help address comorbidities related to hypertension, diabetes, and cardiovascular diseases. Advanced technologies, like artificial intelligence, are being integrated into these devices to optimize treatment plans and improve patient care. Exercise and diet remain essential components of post-surgery recovery, with devices offering support and guidance in these areas. Thus, such factors are driving the growth of the market during the forecast period.

Significant Market Trends

The growing use of robotic-assisted bariatric surgery is the key trend in the market. Obesity, a public health problem affecting millions worldwide, often leads to comorbidities such as hypertension, diabetes, and cardiovascular diseases. Bariatric surgery, a medical approach to weight loss, employs various equipment and devices to facilitate the procedure. These include laparoscopic instruments for minimally invasive approaches, pharmaceutical devices for anesthesia and pain management, and advanced end

The European weight loss surgery market is experiencing robust growth, driven by rising obesity rates, increasing awareness of bariatric procedures, and advancements in minimally invasive surgical techniques. The market, valued at approximately €X million in 2025 (assuming a logical extrapolation based on the provided CAGR of 15% and the unspecified market size "XX" – a precise figure requires the missing "XX" value), is projected to reach €Y million by 2033. This significant expansion is fueled by several key factors. The increasing prevalence of obesity and related comorbidities like type 2 diabetes and cardiovascular disease is creating a substantial demand for effective weight loss solutions. Furthermore, technological advancements in devices such as suturing devices, stapling devices, and implantable gastric bands are leading to safer, less invasive procedures with improved patient outcomes, driving market penetration. The segment of assisting devices, encompassing suturing, closure, and stapling devices, is expected to dominate the market due to its widespread use in various bariatric surgeries. However, the growth is also influenced by factors like high procedure costs, potential complications associated with surgery, and varying reimbursement policies across European countries. Growth across the major European markets – Germany, the United Kingdom, France, Italy, and Spain – will contribute significantly to the overall market expansion. However, disparities in healthcare infrastructure and insurance coverage may lead to regional variations in adoption rates. The competitive landscape includes established players like Allergan, Ethicon, and Covidien, as well as emerging companies focusing on innovative technologies. These companies are constantly investing in research and development to introduce advanced devices and improve surgical techniques, further propelling the market's growth. While regulatory hurdles and potential risks associated with weight loss surgery present challenges, the overall outlook for the European weight loss surgery market remains positive, indicating substantial growth opportunities over the forecast period. (Note: 'X' and 'Y' represent calculated values derived from the 15% CAGR and the missing base market size. To obtain precise figures, the missing market size data is required). Recent developments include: In June 2022, Rhythm Pharmaceuticals, Inc. announced that IMCIVREE is available to patients in Germany.The European Commission granted IMCIVREE marketing authorization for the treatment of obesity and the management of hunger in adults and children aged 6 and older with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1 deficiency or biallelic leptin receptor deficiency., In June 2022, European Medicines Agency (EMA) safety committee Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the withdrawal of European Union (EU) marketing authorisations for amfepramone obesity medicines.. Key drivers for this market are: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Potential restraints include: Increase in Obese Population, Prevalence of Diabetes and Heart Diseases; Government Initiatives to Curb Obesity; Insurance Coverage of Surgeries. Notable trends are: Gastric Balloons Segment is Expected to Witness the Highest CAGR in the Market Over the Forecast Period.

Snapshot img

Smart Weight, Body Composition, And BMI Scales Market Size 2025-2029

The smart weight, body composition, and BMI scales market size is forecast to increase by USD 115.7 million at a CAGR of 5.3% between 2024 and 2029.

The market is experiencing significant growth, driven primarily by the rising health consciousness among individuals worldwide. This trend is particularly prominent in developed economies, where consumers are increasingly focused on maintaining optimal health and fitness. Another key factor fueling market growth is the proliferation of innovative features, such as pregnancy mode, which cater to specific user needs. However, the market is not without challenges. The emergence of alternative smart wearable devices and applications, which offer comprehensive health monitoring capabilities, poses a significant threat to the growth of the market.
Additionally, they integrate with mobile apps, wearable technology, and home automation systems for seamless data visualization and personalized insights. To capitalize on market opportunities and navigate challenges effectively, companies must focus on offering differentiated features, competitive pricing, and seamless integration with other health and wellness platforms. By doing so, they can attract and retain customers, while also positioning themselves as trusted partners in their health journey.

What will be the Size of the Smart Weight, Body Composition, And BMI Scales Market during the forecast period?

Request Free Sample

The market is experiencing significant growth as preventive healthcare and data-driven wellness gain prominence in the global health landscape. This market encompasses advanced body composition analyzers, obesity management tools, and smart bathroom scales, all of which leverage biometric data to provide precision insights into weight, body composition, and overall health status. These devices offer multi-user support, wireless connectivity, and integration into the smart home ecosystem, enabling healthy habits and real-time monitoring of weight loss motivation, cardiovascular health, metabolic syndrome, and diabetic management.
The market is driven by technological convergence, remote patient monitoring, wellness coaching, and data-driven insights, with a focus on bioimpedance technology advancements and family health tracking. The adoption of mobile health (mHealth) solutions further expands the market's reach and potential for widespread impact on lifestyle modification and connected healthcare.

How is this Smart Weight, Body Composition, And BMI Scales Industry segmented?

The smart weight, body composition, and BMI scales industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Distribution Channel

  Offline
  Online


Price

  Less than USD100
  More than USD100


Type

  Wi-Fi
  Bluetooth


Application

  Household
  Gym
  Others


Geography

  North America

    US
    Canada
    Mexico


  Europe

    France
    Germany
    Italy
    Russia


  APAC

    China
    Japan
    South Korea


  South America



  Middle East and Africa

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period. The offline market for smart weight, body composition, and BMI scales has experienced notable growth, catering to consumers who prefer a tangible shopping experience. This segment encompasses traditional retail stores, where customers can examine the products prior to purchase. Various retail channels, including specialty health stores, department stores, hypermarkets, and fitness equipment stores, carry these devices. These outlets often feature dedicated sections for health and wellness products, providing an extensive reach to potential buyers. Smart scales, as part of this category, offer advanced features such as body composition analysis, BMI measurement, body fat percentage assessment, muscle mass evaluation, and more.

These devices play a pivotal role in health monitoring, weight management, fitness tracking, stress management, and chronic disease management. Furthermore, they employ sensor technology, electrode analysis, and machine learning algorithms to deliver accurate and actionable data. Privacy concerns are addressed through data security measures and cloud-based data storage. Overall, the offline market for smart weight, body composition, and BMI scales continues to thrive, offering a diverse range of benefits to healthcare professionals, fitness enthusiasts, competitive athletes, and individuals focused on mental health and wellness.

Get a glance at the market report of share of various segments Request Free Sample

The Offline segment was valued at USD 198.80 million in

As of 2020, roughly 37 percent of adult men were overweight in France. During that year, around 44 percent of French men had a BMI of 18.5 to 24.9, which the index classifies as not overweight. Nonetheless, 16.7 percent of adult men fell under the obesity classification: a BMI of at least 30.